Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric tigecycline versus clindamycin for complicated skin and skin structure infections
2008-001936-11Phase 3Completed
- Sponsor
- Wyeth
- Start
- Mar 2009
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tigecycline, clindamycin and vancomycin in Complicated skin and skin structure infection (cSSSI) and Staphylococcus aureus skin infection (2 arms), sponsored by Wyeth. Primary endpoints: Clinical response rate at test-of-cure in clinically evaluable population and Clinical response rate at test-of-cure in clinical modified intent-to-treat population. Started Mar 2009; status: completed.
02
Drugs
tigecyclineclindamycinvancomycin
03
Conditions
Complicated skin and skin structure infection (cSSSI)Staphylococcus aureus skin infection
Beyond the preview
Go deeper on 2008-001936-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001936-11.